IDEXX Laboratories, Inc. (NASDAQ:IDXX) Shares Bought by LGT Capital Partners LTD.

LGT Capital Partners LTD. boosted its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 3.5% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 143,298 shares of the company’s stock after buying an additional 4,823 shares during the period. IDEXX Laboratories accounts for 2.3% of LGT Capital Partners LTD.’s investment portfolio, making the stock its 16th largest position. LGT Capital Partners LTD. owned 0.17% of IDEXX Laboratories worth $59,245,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. FSA Wealth Management LLC acquired a new position in IDEXX Laboratories during the third quarter worth $25,000. Rialto Wealth Management LLC purchased a new stake in IDEXX Laboratories in the fourth quarter valued at $30,000. Ashton Thomas Securities LLC acquired a new position in shares of IDEXX Laboratories in the 3rd quarter valued at $37,000. Retirement Wealth Solutions LLC acquired a new position in shares of IDEXX Laboratories in the 4th quarter valued at $31,000. Finally, Kestra Investment Management LLC acquired a new position in shares of IDEXX Laboratories in the 4th quarter valued at $38,000. Institutional investors and hedge funds own 87.84% of the company’s stock.

IDEXX Laboratories Price Performance

IDXX opened at $430.12 on Friday. The stock’s 50-day moving average price is $437.37 and its 200 day moving average price is $449.41. IDEXX Laboratories, Inc. has a 12-month low of $398.50 and a 12-month high of $562.25. The company has a current ratio of 1.31, a quick ratio of 0.95 and a debt-to-equity ratio of 0.28. The firm has a market cap of $34.98 billion, a price-to-earnings ratio of 40.31, a PEG ratio of 3.41 and a beta of 1.39.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on IDXX shares. Piper Sandler upped their price target on IDEXX Laboratories from $435.00 to $510.00 and gave the company a “neutral” rating in a research note on Monday, February 10th. Leerink Partners started coverage on IDEXX Laboratories in a research note on Monday, December 2nd. They issued an “outperform” rating and a $500.00 price target on the stock. StockNews.com lowered IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Friday. Leerink Partnrs raised IDEXX Laboratories to a “strong-buy” rating in a research note on Monday, December 2nd. Finally, Morgan Stanley decreased their price target on IDEXX Laboratories from $559.00 to $550.00 and set an “overweight” rating on the stock in a research note on Wednesday, January 29th. Four analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, IDEXX Laboratories presently has an average rating of “Moderate Buy” and an average price target of $533.75.

Insider Buying and Selling at IDEXX Laboratories

In other IDEXX Laboratories news, Director M Anne Szostak sold 3,000 shares of the stock in a transaction dated Friday, February 7th. The stock was sold at an average price of $465.94, for a total value of $1,397,820.00. Following the sale, the director now owns 3,061 shares of the company’s stock, valued at $1,426,242.34. This trade represents a 49.50 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP George Fennell sold 9,986 shares of the stock in a transaction dated Monday, February 10th. The shares were sold at an average price of $462.53, for a total value of $4,618,824.58. Following the completion of the sale, the executive vice president now directly owns 8,176 shares in the company, valued at $3,781,645.28. This represents a 54.98 % decrease in their position. The disclosure for this sale can be found here. 2.11% of the stock is owned by corporate insiders.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.